Hyep Ivan 4
4 · Bicara Therapeutics Inc. · Filed Nov 25, 2025
Insider Transaction Report
Form 4
Hyep Ivan
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-21$3.79/sh+605$2,293→ 145,960 total - Exercise/Conversion
Common Stock
2025-11-24$3.79/sh+17,795$67,439→ 163,150 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-21−605→ 115,979 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (605 underlying) - Sale
Common Stock
2025-11-24$18.55/sh−17,795$330,094→ 145,355 total - Sale
Common Stock
2025-11-21$18.15/sh−605$10,981→ 145,355 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-24−17,795→ 98,184 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (17,795 underlying)
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.